Phase I/II Study to Evaluate the Safety and Tolerability of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection.
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2014
At a glance
- Drugs Pidilizumab (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors CureTech
- 28 Aug 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 Oct 2012 Planned end date changed from 1 Apr 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.
- 21 Feb 2012 Actual patient number 13 added as reported by ClinicalTrials.gov.